Carsten Brunn, Cartesian Therapeutics CEO
December 3, 2024 10:51 AM EST
R&D

Carte­sian tees up Phase 3 mR­NA CAR-T study in myas­the­nia gravis

Lei Lei Wu

News Reporter

Carte­sian Ther­a­peu­tics re­port­ed longer-term re­sults from a mid-stage study of its mR­NA CAR-T ther­a­py for myas­the­nia gravis, sug­gest­ing that the ther­a­py is durable be­yond the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

Co­herus makes fi­nal, $483M piv­ot away from biosim­i­lars

GSK ter­mi­nates Phase 2 tri­al of HBV ther­a­peu­tic vac­cine

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

A service from the Financial Times